deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02174627

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis

Sponsor: AstraZeneca

Conditions Anemia
Interventions Placebo Roxadustat
Updated 20 times since 2017 Last updated: Nov 27, 2019 Started: Jun 26, 2014 Primary completion: Oct 4, 2018 Completion: Oct 4, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02174627, this PHASE3 trial focuses on Anemia and remains completed. Sponsored by AstraZeneca, it has been updated 20 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Nov 2017 · 3 months · monthly snapshot~Nov 2017 – ~Feb 2018 · 3 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Dec 2018 · 4 months · monthly snapshot~Dec 2018 – ~Jan 2020 · 13 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

20 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE3

  2. Nov 2025 — Feb 2026 [monthly]

    Completed PHASE3

  3. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

▶ Show 15 earlier versions

  1. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  2. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE3

  3. Jan 2020 — Jan 2021 [monthly]

    Completed PHASE3

  4. Dec 2018 — Jan 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Aug 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  7. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2018 — May 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Nov 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE3

  10. Aug 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE3

  11. May 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  12. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE3

  13. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  14. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Kyntra Bio
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Aguascalientes, Mexico , Ahmedabad, India , Ajka, Hungary , Almería, Spain , Ankara, Turkey (Türkiye) , Ansan-si, South Korea , Antalya, Turkey (Türkiye) , Arad, Romania , Arkhangelsk, Russia and 255 more locations